SCHEMBL3239163

SCHEMBL3239163

Nc1ncnc2c1c(=O)ccn2-c1ccc(NC(=O)Nc2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.41
KDR P35968 4/20 0.41
FLT1 P17948 4/20 0.40
TEK Q02763 4/20 0.40
RIPK1 Q13546 3/20 0.40
RET P07949 2/20 0.40
PTK2 Q05397 2/20 0.40
PTK2B Q14289 1/20 0.40
NPC1 O15118 2/20 0.39
MAPT P10636 2/20 0.39
RAB9A P51151 2/20 0.39
FPR2 P25090 6/20 0.39
AURKA O14965 2/20 0.39
AURKB Q96GD4 2/20 0.39
KIT P10721 2/20 0.39
DCLK1 O15075 1/20 0.39
DYRK3 O43781 1/20 0.39
ROCK2 O75116 1/20 0.39
MAP4K4 O95819 1/20 0.39
CHEK2 O96017 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3835826 0.89 KDR (0.51) CSF1RKDRFLT1TEKRIPK1
SCHEMBL3240025 0.86 FLT1 (0.41) CSF1RKDRFLT1TEKRIPK1
SCHEMBL3244888 0.85 RIPK1 (0.42) CSF1RKDRFLT1TEKRIPK1
SCHEMBL3834274 0.84 KDR (0.57) CSF1RKDRFLT1TEKRIPK1
SCHEMBL12391534 0.84 KDR (0.48) CSF1RKDRFLT1TEKRET
SCHEMBL3834263 0.83 RIPK1 (0.56) CSF1RKDRFLT1TEKRIPK1
SCHEMBL3833005 0.83 RIPK1 (0.57) CSF1RKDRFLT1TEKRIPK1
SCHEMBL3238527 0.83 RET (0.46) CSF1RKDRFLT1TEKRIPK1
SCHEMBL3830022 0.82 RIPK1 (0.56) KDRRIPK1KITNTRK1FLT3
SCHEMBL3834781 0.82 RIPK1 (0.45) CSF1RKDRFLT1TEKRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745434-B2 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours MERCK PATENT GMBH (DE) 2010-06-29 US claimed
EP-1809630-B1 4-AMINO-5-OXO-8-PHENYL-5H-PYRIDO-[2,3-D]-PYRIMIDINE DERIVATIVES AS TYROSINE KINASE AND RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS MERCK PATENT GMBH (DE) 2009-04-15 EP claimed
US-20080146560-A1 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours MERCK PATENT GMBH (DE) 2008-06-19 US claimed
US-7745434-B2 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours MERCK PATENT GMBH (DE) 2010-06-29 US disclosed
US-7745434-B2 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours MERCK PATENT GMBH (DE) 2010-06-29 US disclosed
US-7745434-B2 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours MERCK PATENT GMBH (DE) 2010-06-29 US disclosed
EP-1809630-B1 4-AMINO-5-OXO-8-PHENYL-5H-PYRIDO-[2,3-D]-PYRIMIDINE DERIVATIVES AS TYROSINE KINASE AND RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS MERCK PATENT GMBH (DE) 2009-04-15 EP disclosed
US-20080146560-A1 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours MERCK PATENT GMBH (DE) 2008-06-19 US disclosed
US-20080146560-A1 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours MERCK PATENT GMBH (DE) 2008-06-19 US disclosed
US-20080146560-A1 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours MERCK PATENT GMBH (DE) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146560-A1 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours TIE1, PDXK, ERBB2 CSF1R 1471/4885KDR 8/4885FLT1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.